Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.

@article{Schmollinger2003MelanomaIO,
  title={Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.},
  author={Jan C. Schmollinger and Robert H. Vonderheide and Kara M. Hoar and Britta Maecker and Joachim L. Schultze and Frank Stephen Hodi and Robert J. Soiffer and Ken Jung and Marcelo J. Kuroda and Norman L. Letvin and Edward A. Greenfield and Martin Mihm and Jeffery L. Kutok and Glenn Dranoff},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2003},
  volume={100 6},
  pages={3398-403}
}
The identification of antigens associated with tumor destruction is a major goal of cancer immunology. Vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor generates potent, specific, and long-lasting antitumor immunity through improved tumor antigen presentation by dendritic cells and macrophages. A phase I clinical trial of this immunization strategy in patients with disseminated melanoma revealed the consistent induction in distant… CONTINUE READING